• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

流感疫苗接种后发生的线性IgA大疱性皮肤病

Linear IgA bullous dermatosis following influenza vaccination.

作者信息

Alberta-Wszolek Lauren, Mousette Alyse M, Mahalingam Meera, Levin Nikki A

机构信息

Division of Dermatology, Department of Medicine, UMass Memorial Healthcare, Worcester, Massachusetts, USA.

出版信息

Dermatol Online J. 2009 Nov 15;15(11):3.

PMID:19951639
Abstract

Linear IgA Bullous Dermatosis (LABD) is an immune-mediated subepidermal vesiculobullous eruption characterized by linear deposits of IgA at the basement membrane zone. Most cases are idiopathic but medications, infections, and malignancies have also been reported to induce LABD. We report the case of a 54-year-old woman who developed LABD shortly after receiving an influenza vaccination.

摘要

线状IgA大疱性皮病(LABD)是一种免疫介导的表皮下水疱大疱性皮疹,其特征是在基底膜带出现IgA线状沉积。大多数病例为特发性,但也有报道称药物、感染和恶性肿瘤可诱发LABD。我们报告一例54岁女性在接种流感疫苗后不久发生LABD的病例。

相似文献

1
Linear IgA bullous dermatosis following influenza vaccination.流感疫苗接种后发生的线性IgA大疱性皮肤病
Dermatol Online J. 2009 Nov 15;15(11):3.
2
Neutrophilic dermatosis of the hands after influenza vaccination.流感疫苗接种后手部嗜中性皮病
Int J Dermatol. 2009 Jan;48(1):66-8. doi: 10.1111/j.1365-4632.2009.03897.x.
3
Linear IgA bullous dermatosis induced by atorvastatin.阿托伐他汀诱发的线状IgA大疱性皮肤病
J Am Acad Dermatol. 2001 Apr;44(4):689-92. doi: 10.1067/mjd.2001.113462.
4
Moxifloxacin as the likely cause of drug-induced linear immunoglobulin A bullous dermatosis.莫西沙星可能是药物性线状免疫球蛋白A大疱性皮肤病的病因。
J Drugs Dermatol. 2008 Aug;7(8):794-5.
5
Linear IgA bullous dermatosis associated with vancomycin and disseminated varicella-zoster infection.与万古霉素及播散性水痘-带状疱疹感染相关的线性IgA大疱性皮肤病
Cutis. 2001 May;67(5):423-6.
6
Linear IgA bullous dermatosis induced by piroxicam.吡罗昔康诱发的线性IgA大疱性皮肤病
J Eur Acad Dermatol Venereol. 1998 Jan;10(1):70-2.
7
Drug-induced linear immunoglobulin A bullous dermatosis mimicking Stevens-Johnson syndrome: a case report.药物性线状免疫球蛋白A大疱性皮肤病酷似史蒂文斯-约翰逊综合征:一例报告
Cutis. 2007 Mar;79(3):203-7.
8
[Drug induced linear IgA bullous dermatosis].[药物性线状IgA大疱性皮肤病]
Nephrologie. 2003;24(6):287-92.
9
Linear IgA bullous dermatosis in one of two piroxicam-induced eruptions: a distinct direct immunofluorescence trend revealed by the literature.两种吡罗昔康诱发的皮疹之一为线状IgA大疱性皮肤病:文献揭示的一种独特的直接免疫荧光趋势
J Am Acad Dermatol. 2001 Nov;45(5):691-6. doi: 10.1067/mjd.2001.117390.
10
Linear IgA bullous dermatosis induced by interferon-alpha 2a.
Clin Exp Dermatol. 2009 Jul;34(5):e123-4. doi: 10.1111/j.1365-2230.2008.03160.x.

引用本文的文献

1
Linear IgA bullous dermatosis-a fifty year experience of Warsaw Center of bullous diseases.线状IgA大疱性皮肤病——华沙大疱性疾病中心五十年经验
Front Immunol. 2025 Jan 14;15:1478318. doi: 10.3389/fimmu.2024.1478318. eCollection 2024.
2
Eosinophil-rich linear IgA bullous dermatosis induced by mRNA COVID-19 booster vaccine.mRNA COVID-19 加强疫苗诱导的嗜酸性粒细胞丰富的线性 IgA 大疱性皮肤病。
J Cutan Pathol. 2023 Jan;50(1):24-28. doi: 10.1111/cup.14305. Epub 2022 Aug 23.
3
Linear IGA bullous dermatosis potentially triggered by vaccination.
线性 IgA 大疱性皮肤病可能由疫苗接种引发。
Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:20587384211021218. doi: 10.1177/20587384211021218.
4
Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine.接种牛津-阿斯利康 COVID-19 疫苗后发生线性 IgA 大疱性皮病。
Clin Exp Dermatol. 2022 Mar;47(3):611-613. doi: 10.1111/ced.15007. Epub 2021 Dec 8.
5
Previously misdiagnosed linear IgA dermatosis resolved with dapsone.先前被误诊的线状IgA大疱性皮病使用氨苯砜后病情得到缓解。
BMJ Case Rep. 2018 Apr 25;2018:bcr-2017-220623. doi: 10.1136/bcr-2017-220623.
6
Pemphigus vulgaris: A dermatological sequel of severe H1N1 infection.寻常型天疱疮:严重甲型H1N1感染的皮肤后遗症。
Indian Dermatol Online J. 2014 Apr;5(2):216-7. doi: 10.4103/2229-5178.131131.